Bristol-Myers Squibb Co.
Article Abstract:
Bristol-Myers Squibb Co.'s accounting problems with the SEC, expiring patents without drug development to offset declines in sales and severe generic competition for key drugs continue to weigh heavily on the company. Stock price are not likely to recover soon so only a healthy dividend payout remains as a long term comfort to investors.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Nektar Therapeutics Inc
Article Abstract:
FDA approval for Nektar Therapeutics Inc.'s inhaleable insulin product designed for diabetics is slated for 2005 but the company may run out of cash for research and development before the date. Investors are advised to steer clear of this stock.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Myland Laboratories Inc
Article Abstract:
Mylan Laboratories Inc. was helped by its Buspirone sales in ending fiscal 2002 slightly higher than 2001's figures. Shares have subpar long-term capital-gains potential.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: